Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes
Journal of Virology · 22.07.2025 · 99 (7)
DOI: 10.1128/jvi.00465-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 22.07.2025. Verfasst von Caitlin Harris und 21 weiteren Autor:innen. Beteiligte Einrichtung: Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Spike Glycoprotein, Coronavirus, COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
SARS-CoV-2 continues to evolve, with new variants emerging that evade pre-existing immunity and limit the efficacy of existing vaccines. One approach toward developing superior, variant-proof vaccines is to engineer immunogens that preferentially elicit antibodies with broad cross-reactivity against SARS-CoV-2 and its variants by targeting conserved epitopes on spike. The inner and outer faces of the receptor binding domain (RBD) are two such conserved regions targeted by antibodies that recognize diverse human and animal coronaviruses. To promote the elicitation of such antibodies by vaccination, we engineered “resurfaced” RBD immunogens that contained mutations at exposed RBD residues outside the target epitopes. In the context of pre-existing immunity, these vaccine candidates aim to disfavor the elicitation of strain-specific antibodies against the immunodominant receptor binding motif (RBM) while boosting the induction of inner and outer face antibodies. The engineered resurfaced RBD immunogens were stable, lacked binding to monoclonal antibodies with limited breadth, and maintained strong interactions with target broadly neutralizing antibodies. When used as vaccines, they limited humoral responses against the RBM as intended. Multimerization on nanoparticles further increased the immunogenicity of the resurfaced RBD immunogens, thus supporting resurfacing as a promising immunogen design approach to rationally shift natural immune responses to develop more protective vaccines. IMPORTANCE SARS-CoV-2 is the third coronavirus to cause significant human disease over the last two decades. Despite their success in preventing serious disease, current SARS-CoV-2 vaccines must be updated regularly to match the circulating strains for continued protection. Therefore, it would be advantageous to develop vaccines that protect more broadly against SARS-CoV-2, its variants, and other pre-emergent coronaviruses. This may be achieved by preferentially eliciting antibodies against conserved regions of the spike protein that decorates the virus. Toward this goal, we engineered vaccine candidates to target the conserved inner and outer domains of the Receptor Binding Domain of SARS-CoV-2, by altering the surface of the wild-type protein such that strain-specific antibodies that bind outside these regions are no longer recognized. When used in animals with pre-existing SARS-CoV-2 immunity, these molecules reduce the elicitation of variant-specific antibodies, thus providing a blueprint to alter the natural immunodominance hierarchies of SARS-CoV-2 proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Cell Biology, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Microbiology and Molecular Genetics, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Integrative Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Caitlin Harris, Thomas Oguin, Barton F Haynes, Mihai L Azoitei
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Harris, C., Kapingidza, A. B., San, J. E., Christopher, J., Gavitt, T., Rhodes, B., Janowska, K., O'Donnell, C., Lindenberger, J., Huang, X., Sammour, S., Berry, M., Barr, M., Parks, R., Newman, A., Overton, M., Oguin, T., Acharya, P., Haynes, B. F., …, & Azoitei, M. L. (2025). Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes. Journal of Virology, 99(7). https://doi.org/10.1128/jvi.00465-25
Vancouver
Harris C, Kapingidza AB, San JE, Christopher J, Gavitt T, Rhodes B, et al. Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes. Journal of Virology. 2025;99(7). doi:10.1128/jvi.00465-25
BibTeX
@article{Harris2025,
author = {Harris, Caitlin and Kapingidza, A Brenda and San, James E and Christopher, Jayani and Gavitt, Tyler and Rhodes, Brianna and Janowska, Katarzyna and O'Donnell, Christopher and Lindenberger, Jared and Huang, Xiao and Sammour, Salam and Berry, Madison and Barr, Maggie and Parks, Rob and Newman, Amanda and Overton, Mary and Oguin, Thomas and Acharya, Priyamvada and Haynes, Barton F and Saunders, Kevin O and Wiehe, Kevin and Azoitei, Mihai L},
title = {Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes},
journal = {Journal of Virology},
year = {2025},
volume = {99},
number = {7},
doi = {10.1128/jvi.00465-25}
}
EUVIMED